AXL and hepatocellular carcinoma: To investigate whether AXL and MET are involved in the Galectin-1-mediated sorafenib sensitization of HCC cells, we treated Huh-7/SR cells with the AXL inhibitor R428 and the MET inhibitor GSK1363089 and analyzed AXL, MET, and Galectin-1 protein expression through Western blotting.